Robert E. Martell

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Guillermo Garcia‐Manero, Sarit Assouline, Jörge E. Cortes et al. · Blood · 2008 · 234 citations · Full text

Medicine, Oncology, Pharmacology +10

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

Anas Younes, Yasuhiro Oki, R. Gregory Bociek et al. · The Lancet Oncology · 2011 · 195 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011

Vicki A. Morrison, Bercedis L. Peterson, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2001 · 142 citations

Medicine, Infectious Diseases, Oncology +15

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

Lillian L. Siu, Ignacio Durán, Wells A. Messersmith et al. · Journal of Clinical Oncology · 2008 · 118 citations

Medicine, Oncology, Pharmacology +16

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Elisabeth I. Heath, Keith C. Bible, Robert E. Martell et al. · Investigational New Drugs · 2007 · 118 citations

Medicine, Oncology, Pharmacology +16